Skip to main content

Pharma RSS Digest - 2026-05-03

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The May 3, 2026 digest reflects a light news cycle with two substantive wire releases both tagged to the regulatory/approval theme. BioMarin dominated the day's coverage with long-term VOXZOGO data, reinforcing its position in the rare skeletal dysplasia space through sustained efficacy and bone health evidence spanning up to eight years. Meanwhile, the Foundation Fighting Blindness honored Dr. Eric Pierce, spotlighting the maturation of in vivo gene therapy from LUXTURNA's landmark 2017 approval through the pioneering BRILLIANCE CRISPR trial. Together, these stories highlight continued investment in rare genetic diseases, though neither represents an immediate regulatory catalyst—rather, they reflect the ongoing data accumulation and personnel recognition that underpin future commercial expansion in this space.

Key Developments​

BioMarin strengthens VOXZOGO's long-term profile at PES 2026. BioMarin presented eight-year extension data at the Pediatric Endocrine Society Annual Meeting in San Francisco on May 1-2, demonstrating sustained height gains in children with achondroplasia who initiated therapy after age five—reaching a mean difference of 13.59 cm versus untreated cohorts (p<0.0001). A separate six-year study of 119 children showed increasing bone mineral content alongside consistent bone mineral density Z-scores, addressing long-term skeletal safety concerns. The arm span data also indicated proportional skeletal growth, reinforcing that treatment does not distort natural body proportions. This long-term evidence gives prescribers greater confidence in early intervention and creates a substantial clinical barrier for any future competitors in the dwarfism space. Investors should monitor Phase 3 CANOPY-HCH-3 topline results for hypochondroplasia, expected in the first half of 2026, which could expand VOXZOGO's addressable population beyond achondroplasia. A regulatory submission for hypochondroplasia remains possible in the second half of 2026 if those results are positive.

Dr. Eric Pierce receives Foundation Fighting Blindness' top honor, highlighting gene therapy's ascent. Dr. Pierce, Director of the Ocular Genomics Institute at Massachusetts Eye and Ear, was named the 2026 recipient of the Llura Liggett Gund Award on May 1 for his contributions to inherited retinal disease research spanning more than 25 years. His work directly enabled LUXTURNA's 2017 FDA approval—the first in vivo gene therapy for an inherited disease—and he led the BRILLIANCE trial, the world's first in vivo CRISPR-Cas9 genome-editing study in humans, which showed vision improvements in 11 of 14 participants with CEP290 mutations. The recognition underscores how foundational scientific contributions translate into clinical breakthroughs, establishing a template for other genetic disease areas. The BRILLIANCE results, published in the New England Journal of Medicine in 2024, continue to validate CRISPR-Cas9 as a viable in vivo therapeutic approach. The field's progress raises questions about long-term durability of edits and accessibility of these high-cost therapies, but Pierce's recognition signals continued momentum in translating genome editing from bench to bedside.

Watchlist​

  • BioMarin topline Phase 3 results for hypochondroplasia (CANOPY-HCH-3) remain pending; success would trigger regulatory submission timeline. Source

  • Long-term safety data for VOXZOGO beyond eight years remains limited; continued monitoring will be necessary as the treated population ages. Source

  • CRISPR-based treatments for inherited retinal diseases remain early in clinical availability; cost and accessibility challenges have not yet been addressed industry-wide. Source